Juhan Lee

Juhan Lee

Auto-generated profile, based on publicly available information

Juhan Lee

Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EKEun Jin Kim
Eun Jin Kim
KHKyu Ha Huh
Kyu Ha Huh
BKBeom Seok Kim
Beom Seok Kim
MKMyoung Soo Kim
Myoung Soo Kim
SKSoon Il Kim
Soon Il Kim
JLJuhan Lee
Juhan Lee
High intra-patient variability (IPV) of tacrolimus trough concentrations is increasingly recognized as a predictor of poor long-term outcomes in kidney transplant. However, there is a lack of information regarding the association between tacrolimus IPV and graft outcomes according to immunological risk. We analyzed tacrolimus IPV using the coefficient of variability from months 6–12 after transplantation in 1080 kidney transplant recipients. Patients were divided into two immunological risk groups based on pre-transplant panel reactive antibodies and donor-specific antibodies. High immunological risk was defined as panel reactive antibodies ≥ 20% or the presence of donor-specific antibodies. The effects of tacrolimus IPV on graft outcomes were significantly different between low and high immunological risk patients. A multivariable Cox regression model confirmed that high tacrolimus IPV was an independent risk factor for graft failure in the high risk group (HR, 2.90; 95% CI, 1.42–5.95, P = 0.004). In the high risk group, high tacrolimus IPV was also significantly associated with increased risk of antibody-mediated rejection (P = 0.006). In contrast, death-censored graft survival and antibody-mediated rejection in the low immunological risk group was not significantly different by tacrolimus IPV. High tacrolimus IPV significantly increases the risk of graft failure and antibody-mediated rejection in patients with high immunological risk.

20 October 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JLJuhan Lee
Juhan Lee
SSSeung Hwan Song
Seung Hwan Song
JLJee Youn Lee
Jee Youn Lee
DKDeok Gie Kim
Deok Gie Kim
JLJae Geun Lee
Jae Geun Lee
KHKyu Ha Huh
Kyu Ha Huh
The effect of delayed graft function (DGF) recovery on long-term graft outcome is unclear. The aim of this study was to examine the association of DGF recovery status with long-term outcome. We analyzed 385 recipients who underwent single kidney transplantation from brain-dead donors between 2004 and 2015. Patients were grouped according to renal function at 1 month post-transplantation: control (without DGF); recovered DGF (glomerular filtration rate [GFR] ≥ 30 mL/min/1.73 m2); and incompletely recovered DGF group (GFR < 30 mL/min/1.73 m2). DGF occurred in 104 of 385 (27%) recipients. Of the DGF patients, 70 recovered from DGF and 34 incompletely recovered from DGF. Death-censored graft survival rates for control, recovered DGF, and incompletely recovered DGF groups were 95.3%, 94.7%, and 80.7%, respectively, at 5 years post-transplantation (P = 0.003). Incompletely recovered DGF was an independent risk factor for death-censored graft loss (HR = 3.410, 95%CI, 1.114-10.437). DGF was associated with increased risk for patient death regardless of DGF recovery status. Mean GFRs at 5 years were 65.5 ± 20.8, 62.2 ± 27.0, and 45.8 ± 15.4 mL/min/1.73 m2 for control, recovered, and incompletely recovered DGF groups, respectively (P < 0.001). Control group and recovered DGF patients had similar renal outcomes. However, DGF was associated with increased risk for patient death regardless of DGF recovery status.

12 January 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
HKHyun Jeong Kim
Hyun Jeong Kim
NHNamki Hong
Namki Hong
HKHyung Woo Kim
Hyung Woo Kim
JYJaeseok Yang
Jaeseok Yang
BKBeom Seok Kim
Beom Seok Kim
JLJuhan Lee
Juhan Lee
Muscle wasting in chronic kidney disease is associated with increased cardiovascular events, morbidity, and mortality. However, whether pretransplantation skeletal muscle mass affects kidney transplantation (KT) outcomes has not been established. We analyzed 623 patients who underwent KT between 2004 and 2019. We measured the cross-sectional area of total skeletal muscle at the third lumbar vertebra level on pretransplantation computed tomography scan. The patients were grouped into low and normal skeletal muscle mass groups based on the sex-specific skeletal muscle mass index lowest quartile. During the entire follow-up period, 45 patients (7.2%) died and 56 patients (9.0%) experienced death-censored graft loss. Pretransplantation low skeletal muscle mass was independently associated with all-cause mortality (adjusted hazard ratio, 2.269; 95% confidence interval, 1.232-4.182). Low muscle mass was also associated with an increased risk of hospital readmission within 1 year after transplantation. Death-censored graft survival rates were comparable between the 2 groups. The low muscle group showed higher creatinine-based estimated glomerular filtration rates (eGFRs) than the normal muscle group. Although cystatin C-based eGFRs were measured in only one-third of patients, cystatin C-based eGFRs were comparable between the 2 groups. Pretransplantation low skeletal muscle mass index is associated with an increased risk of mortality and hospital readmission after KT.

17 June 2024 in International Journal of Surgery
Verified
Journal Article
Open access
AHAhram Han
Ahram Han
AJAe Jeong Jo
Ae Jeong Jo
HKHyunwook Kwon
Hyunwook Kwon
YKYoung Hoon Kim
Young Hoon Kim
JLJuhan Lee
Juhan Lee
SMSangil Min
Sangil Min
Background: The current study aimed to determine the optimal tacrolimus trough levels for balancing graft survival and patient safety following kidney transplantation. Materials and methods: We conducted a retrospective cohort study involving 11 868 kidney transplant recipients from five medical centers. The association between tacrolimus exposures (periodic mean trough level, coefficient of variability, time in therapeutic range) and composite allograft outcome (de novo donor-specific antibody, biopsy-proven rejection, kidney dysfunction, and graft failure), as well as safety outcomes (severe infection, cardiovascular events, malignancy, and mortality) were assessed. Data were sourced from Clinical Data Warehouses and analyzed using advanced statistical methods, including Cox marginal structural models with inverse probability treatment weighting. Results: Tacrolimus levels of 5.0–7.9 ng/ml and 5.0–6.9 ng/ml during the 2–12 month and 12–72 month post-transplantation periods, respectively, were associated with reduced risks of composite allograft outcomes. During the first post-transplant year, the adjusted hazard ratios (aHR) for composite allograft outcomes were 0.69 (95% CI 0.55–0.85, P<0.001) for 5.0–5.9 ng/ml; 0.81 (95% CI 0.67–0.98, P=0.033) for 6.0–6.9 ng/ml; and 0.73 (95% CI 0.60–0.89, P=0.002) for 7.0–7.9 ng/ml (compared to levels ≥8.0 ng/ml). For the 6-year composite outcomes, aHRs were 0.68 (95% CI 0.53–0.87, P=0.002) for 5.0–5.9 ng/ml and 0.65 (95% CI 0.50–0.85, P=0.001) for 6.0–6.9 ng/ml. These optimal ranges showed reduced rates of severe infection (6 years), malignancy (6 years), and mortality (1 year). Conclusion: This multicenter study provides robust evidence for optimal tacrolimus trough levels during the periods 2–12 and 12–72 months following kidney transplantation.

28 September 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HKHyun Jeong Kim
Hyun Jeong Kim
JLJuhan Lee
Juhan Lee
JLJae Geun Lee
Jae Geun Lee
DJDong Jin Joo
Dong Jin Joo
MKMyoung Soo Kim
Myoung Soo Kim
Tacrolimus is the mainstay of immunosuppression in liver transplantation to prevent rejection. However, the clinical use of tacrolimus is complicated by its narrow therapeutic window and significant intra-patient variability (IPV). High tacrolimus IPV is associated with overexposure and adverse effects, including malignancy. The effects of tacrolimus IPV in liver transplant recipients with and without hepatocellular carcinoma (HCC) are unknown. We investigated the association between tacrolimus IPV and transplant outcomes in 636 liver transplant patients. Tacrolimus IPV was determined by calculating the coefficient of variance (CV) of outpatient tacrolimus trough levels from 3 to 12 months after transplantation. High tacrolimus IPV was defined as CV > 30%. Patients were grouped according to tacrolimus IPV and HCC status. Among 636 liver transplant patients, 349 had HCC and 287 had no HCC. Overall survival in HCC patients was significantly reduced with high tacrolimus IPV (P < 0.001), whereas survival of non-HCC patients was not associated with tacrolimus IPV. Multivariable analysis confirmed the independent association between high tacrolimus IPV and overall mortality in HCC patients (HR, 3.010; 95% CI, 1.084–4.918). HCC recurred in 59 patients (16.9%) post-transplantation. After adjusting for donor/recipient factors, immunosuppression, and tumor characteristics, high tacrolimus IPV was independently associated with an increased risk of HCC recurrence (HR, 2.196; 95% CI, 1.272–3.791). High tacrolimus IPV was associated with significantly increased risks of overall mortality and HCC recurrence in liver transplant recipients with HCC.

1 January 2023 in Journal of Cardiovascular Imaging
Verified
Journal Article
Open access
DKDarae Kim
Darae Kim
MKMinjeong Kim
Minjeong Kim
JPJae Berm Park
Jae Berm Park
JLJuhan Lee
Juhan Lee
KHKyu Ha Huh
Kyu Ha Huh
CSChi Young Shim
Chi Young Shim
Kim D, et al. J Cardiovasc Imaging. 2023 Jan;31:e10. https://doi.org/10.4250/jcvi.2022.0125